SecBot SecBot

KALV

KalVista Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001348911 Biotech & Drug Discovery
No price
Median target
$27.00
range $27.00–27.00
Short interest
6.84M
−43.2%
Days to cover
2.0
at average volume
Insider net
$0
no open-market trades · since Jun 11
New fund stakes
0
Q2 2026 13F · 15 exits
Filing reports
12
analyzed by SecBot
SecBot read BEARISH 5 reports · latest
Balance 2 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/5

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Jun 11. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 15 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.379 → −$0.287 over 90 days. 4 up, 2 down in 30 days.

  • Short sellersCOVERING

    Short interest −43.2% to 6.84M shares. 2.0 days to cover.

Who's buying

13F· Q2 2026
0
new positions
15
exits

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action May 2026
Recent actions
DateFirmActionRating
May 1, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Apr 30, 2026Needham
DOWNGRADE
DOWNGRADEHold
Mar 26, 2026Stifel
MAINTAIN
MAINTAINBuy
Mar 26, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Mar 25, 2026Needham
MAINTAIN
MAINTAINBuy
Jan 9, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · since Jun 11
DateInsiderTypeValue
Jun 11, 2026
Piekos Brian
Chief Financial Officer
Jun 11, 2026
TO ISSUER21,661 sh
Jun 11, 2026
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
Jun 11, 2026
TO ISSUER479,989 sh
Jun 11, 2026
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Jun 11, 2026
TO ISSUER229,918 sh
Jun 11, 2026
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Jun 11, 2026
TO ISSUER25,000 sh
Jun 11, 2026
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Jun 11, 2026
TO ISSUER53,500 sh
Jun 11, 2026
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
Jun 11, 2026
TO ISSUER125,001 sh
Jun 11, 2026
Piekos Brian
Chief Financial Officer
Jun 11, 2026
TO ISSUER100,000 sh
Jun 11, 2026
Piekos Brian
Chief Financial Officer
Jun 11, 2026
TO ISSUER55,000 sh

Earnings setup

Estimates
−$0.29
EPS estimate, this quarter
+24%
estimate change, 90 days
4↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.29-$0.43–-$0.02-10.3%$49.2M
Next Q🔒 Fresh data, subscribers only
Current FY-$0.88-$1.70–$0.59-9.2%$213.5M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· May 29, 2026
6,842,479
shares short
-43.2%
vs prior settlement
2.0
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Aug 25, 2026 Clinical trial readout
Results Pending: KVD900 600 mg (Phase 3), Completed 90d ago
Trial: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for O
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
Capital World Investors · EXIT
0 shares ($0.00)
Jun 22, 2026 SEC
KalVista Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective June 22…
15-12G · Impact 7/10
Jun 17, 2026 SEC
KalVista Pharmaceuticals' shelf registration statement (Form S-3, File No. 333-280759) was declared effective by the…
EFFECT · Impact 3/10
Jun 11, 2026 SEC
Chiesi Farmaceutici S.p.A. completed its acquisition of KalVista Pharmaceuticals for $27.00 per share in cash through…
8-K · Impact 5/10
Jun 11, 2026 Insider
Piekos Brian disposed of 21,661 shares
Chief Financial Officer
Jun 11, 2026 Insider
Palleiko Benjamin L disposed of 479,989 shares
CHIEF EXECUTIVE OFFICER
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

12 filings · 1 bullish · 6 bearish · 5 neutral
All KALV filing & press-release reports (12)